WuXi NextCODE Raises $75 Million in Series B Financing to Accelerate Growth of Global...

WuXi would like to congratulate WuXi NextCODE for raising $75 million in Series B financing, led by the company's current investors Temasek and Yunfeng Capital. WuXi NextCODE will focus the use of proceeds...

LabNetwork Integrates with Reaxys to Offer Seamless Experience from Chemistry Research to Purchase

We look forward to the new collaboration between LabNetwork, WuXi AppTec’s global chemistry ecommerce platform company, and Elsevier, a world-leading provider of scientific, technical and medical information products and services. Under the...

WuXi Biologics Receives Asia-Pacific Best Bioprocessing Excellence Award from IMAPAC

We are pleased to announce that WuXi Biologics  has received the 2017 Asia-Pacific Best Bioprocessing Excellence Award from IMAPAC, a leading consulting firm. WuXi Biologics has been recognized for its outstanding performance for...

WuXi AppTec Lab Testing Division’s Bioanalytical Service Unit Passed FDA Inspection

We are pleased to announce that WuXi’s  Lab Testing Division(LTD)’s Bioanalytical facility in Shanghai once again passed US FDA’s bioequivalence (BE) inspection with no 483 observations. The inspectors from FDA thoroughly audited...

WuXi AppTec Acquires Biology Focused R&D Service Leader HD Biosciences

We are excited to announce that WuXi has acquired HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO). After completion of acquisition, HD Biosciences will become...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS